Injection Pen Market: Increasing prevalence of chronic diseases is projected to boost the market growth at a healthy CAGR of 6.90%. :

Pune, India, June 2022 /MRFR Press Release/- Market Research Future has published a half-cooked research report on the global injection pen market.

Market Highlights

The Injection Pen Market is anticipated to reach USD 73.67 billion by 2030 at  6.90 CAGR during the forecast period 2022-2030. The injection pen is a standard delivery device for accurate subcutaneous delivery. A number of factors such as increasing prevalence of chronic diseases, ongoing technological advancements, and improving regulatory framework are fueling the growth of the global injection pen market. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult population were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040.

Moreover, technological advancements in injection pens and increasing product launch by prominent players are likely to drive the market growth during the forecast period. For instance, in 2017, Sanofi launched AllStar pro reusable pen injector across the European market.  Furthermore, the increasing application of injection pen in the treatment of various chronic diseases, lifestyle diseases and infertility problems enhance the market growth. Additionally, in November 2017, Merck announced the approval of its new GONAL-f RFF Redi-ject (follitropin alfa injection) prefilled pen by the U.S. FDA.

However, certain issues such as reimbursement issues in the developing nations and presence of alternative drug delivery devices can hamper the growth of the market.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Injection Pen Market Research Report

Regional Analysis

The Americas is likely to dominate the global injection pen market owing to the increasing prevalence of cancer and diabetes in the population during the forecast period. In addition, well-established healthcare sector, favorable reimbursement scenario, and growing number of regulatory approvals further drive the growth of the market. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. Europe is likely to hold the second position in the global injection pen market. The market growth is attributed to the availability of funds for research, increasing prevalence and government support for research and development. The Asia Pacific is the fastest growing market owing to the huge patient pool with chronic diseases and increasing healthcare expenditure. For instance, according to the WHO (2016), in China, 10% of adults were diagnosed with diabetes. It also stated that type 2 diabetes was found to be the most prevalent type of diabetes in China. The Middle East and Africa injection pen market are expected to grow slowly during the forecast period. Moreover, in this region, Middle East accounts for largest share owing to the increasing presence of prominent market players in the recent years.


The global injection pen market is segmented on the basis of the type, product, therapy, distribution channel, and end users. On the basis of the type, the market is classified into disposable injection pens and reusable injection pens. The global injection pen market on the basis of product is segmented into insulin pens and pen needles. On the basis of the therapy, the market is segmented as diabetes, growth hormone therapy, fertility, osteoporosis, multiple sclerosis, cardiovascular diseases, rheumatoid arthritis, obesity, Crohn’s disease, cancer, and others. Diabetes is further segmented into insulin and GLP-1.On the basis of distribution channel is segmented into hospital pharmacies, retail pharmacies, online medical stores, and diabetes clinics. On the basis of end users, the global injection pen market is segmented into home care and hospitals & clinics.

Global Injection Pen Key Players

Some the prominent players in the global injection pen market are  Novo Nordisk (Denmark), Eli Lilly (U.S.), Sanofi (France), Merck (U.S.), Ypsomed (Switzerland), AstraZeneca (U.K.), F.Hoffman-La Roche (Switzerland), Becton Dickinson and Company (US), Owen Mumford (U.K.), Novartis (Switzerland), Pfizer (U.S.), Haselmeier (Switzerland), Jiangsu Delfu medical device Co. Ltd (China), and Biocon Ltd (India).